Page 433 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

Challengepercent5CDocs-challenged-in-10-3-listpercent5C145-
ZY200187608-7614.pdf.

(82) Drug Industry Document Archive [Internet]. [cited 2012 Mar 24].
Available from: http://dida.library.ucsf.edu/.

(83) Drug Industry Document Archive—Search Results [Internet].
[cited 2012 Mar 24]. Available from: http://dida.library.ucsf.edu/tid/
anu38h10.

(84) Ibid.
(85) Ross, J.S., K.P. Hill, D.S. Egilman, and H.M. Krumholz. 2008. Guest
authorship and ghostwriting in publications related to rofecoxib: A case
study of industry documents from rofecoxib litigation. Journal of the
American Medical Association 299: 1800–1812.
(86) POGO Letter to NIH on Ghostwriting Academics [Internet]. Project
On Government Oversight. [cited 2012 Mar 24]. Available from: www.pogo
.org/pogo-files/letters/public-health/ph-iis-20101129.html.
(87) http://www.nytimes.com/2010/11/30/business/30drug.html.
(88) http://pogoblog.typepad.com/pogo/gw-attachment-e.html.
(89) Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers
in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.
(90) Matheson A. How Industry Uses the ICMJE Guidelines to Ma-
nipulate Authorship—And How They Should Be Revised. PLoS Med.
2011;8(8):e1001072.
(91) Dyer O. Journal rejects article after objections from marketing
department. BMJ. 2004 Jan 31;328(7434):244–b–244.
(92) Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Jour-
nals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.

433